Zacks: Brokerages Anticipate XOMA Co. (XOMA) Will Post Quarterly Sales of $4.12 Million
Analysts expect that XOMA Co. (NASDAQ:XOMA) will post $4.12 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for XOMA’s earnings, with the lowest sales estimate coming in at $2.33 million and the highest estimate coming in at $5.91 million. XOMA reported sales of $520,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 692.3%. The company is scheduled to report its next quarterly earnings results on Thursday, March 15th.
According to Zacks, analysts expect that XOMA will report full-year sales of $4.12 million for the current year, with estimates ranging from $49.70 million to $53.24 million. For the next year, analysts expect that the company will report sales of $23.90 million per share, with estimates ranging from $23.61 million to $24.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for XOMA.
A number of research firms recently commented on XOMA. HC Wainwright set a $38.00 target price on shares of XOMA and gave the stock a “buy” rating in a research note on Thursday, December 7th. Wedbush reiterated a “buy” rating and issued a $33.00 target price on shares of XOMA in a research note on Tuesday, December 19th. TheStreet upgraded shares of XOMA from an “e+” rating to a “c-” rating in a research note on Wednesday, November 29th. Finally, Zacks Investment Research upgraded shares of XOMA from a “hold” rating to a “strong-buy” rating and set a $33.00 target price for the company in a research note on Friday, November 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $38.33.
Shares of XOMA (NASDAQ XOMA) opened at $28.94 on Monday. The company has a market cap of $235.69, a P/E ratio of -4.03 and a beta of 3.03. The company has a debt-to-equity ratio of 3.53, a current ratio of 3.45 and a quick ratio of 3.45. XOMA has a 12 month low of $4.63 and a 12 month high of $37.25.
WARNING: This article was reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/zacks-brokerages-anticipate-xoma-co-xoma-will-post-quarterly-sales-of-4-12-million/1908336.html.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.